Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
- Status
- TERMINATED
- Phase
- PHASE3
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
- Status
- TERMINATED
- Phase
- PHASE1
Azacitidine and Pembrolizumab in Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab in Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab + Idelalisib for Lung Cancer Study
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
- Status
- UNKNOWN
- Phase
- PHASE2
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
- Status
- COMPLETED
- Phase
- PHASE2
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
- Status
- TERMINATED
- Phase
- PHASE2
Anti-platelet + Pembro for H&N Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- WITHDRAWN
- Phase
- PHASE1